Cryosite Ltd
Company Profile
- Business description- Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions. 
- Contact- 13a Ferndell Street 
 South Granville
 SydneyNSW2142
 AUS- T: +61 288652000 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Diagnostics & Research - Fiscal Year End- 30 June 2026 - Employees- 25 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% | 
| CAC 40 | 8,145.97 | 11.32 | -0.14% | 
| DAX 40 | 24,028.37 | 90.52 | -0.38% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,731.68 | 28.38 | -0.29% | 
| HKSE | 25,906.65 | 376.04 | -1.43% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% | 
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% | 
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |